All News

A recent poll reported that most Americans think drug prices are unreasonably high, but that 76% of Republicans prefer market competition over government regulation to lower prices. Stephen Littlejohn imagines what Donald Trump would say on the matter.

August 11, 2015.

An internal audit of payment practices in Eastern Europe has revealed payments for elaborate travel for government health authorities and state-employed physicians in exchange for approval and prescription of your products. What is the first thing you should do? Lawyer Mara Senn offers some advice.

Amgen and Sandoz received a decision from the U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday. PharmExec spoke with legal and biosimilar experts for their initial reactions.

July 9, 2015.

Not so long ago, pharmaceutical brand managers considered drug packaging an afterthought. Today, packaging not only matters, it is quickly becoming one of the most important considerations in the growth and success of any drug product. Manufacturers now consider innovative, smart packaging that pleases patients in their new roles as consumers, and encourages brand loyalty to be a game changer in an increasingly competitive and crowded biopharmaceutical market.

Sponsored contentThe term “patient centric” has become an almost catch-all term. Cheryl Lubbert looks at the broad range of its application. A review of how patient centricity is being applied shows that it is all of these things and more. A look at just a few different uses of the term shows the broad range of its application:

Watching the latest volleys fly in the ongoing specialty drug pricing wars, Tom Norton wonders: Is it possible that all involved couldn’t just step back and take a breath?

Tactics pharma leaders can implement to stem the continued global threat of counterfeit drugs.

Is it time to view cell therapy companies differently on Wall Street-even distinct from biotech?

Last week’s announcement by UnitedHealth Group of its planned acquisition of pharmacy benefits manager (PBM) Catamaran for $12.8 billion officially puts the pharmaceutical industry on notice that the “war” on drug prices is escalating, writes Michael Griffith.

Does patient choice matter to antitrust enforcers?

In reaction to AbbVie’s massive acquisition of Pharmacyclics, investors who were caught unprepared are looking for ways they could have predicted the deal. Casey McDonald looks at the reaction on Twitter.

The cholesterol-fighting market is back with a vengeance; plenty of complications in store

How pharma can finally put true meaning behind its juiced-up jargon and turn the bluster into reality.

Two commercial marketing experts discuss how this mission critical function must change to stay relevant in bringing new therapies to the patients who need them.

As we wrap up the week in San Francisco, here’s PharmExec's brief rundown of some of the top tweets of the week from JP Morgan and Biotech Showcase.

Click on the links below to download Pharmaceutical Executive's media kits.

With its new healthcare insurance scheme, Jaminan Kesehatan Nasional (JKN), aiming to cover all citizens by 2019, next year will see Indonesia emerge as the most promising emerging market for pharma investment, according the Frost & Sullivan’s Reenita Das.

Building an effective drug forecasting model today requires a revamped approach.

At first glance Obamacare developments for the American Rx industry in 2015 appear fairly benign. However, digging deeper suggests that each, in its own way, could cause various actions with potential for substantial uncertainty for the U.S. pharmaceutical industry next year. If your response to this profound observation was, “Really, what’s new?” - read on.

Pharm Exec profiles Express Scripts' Chief Medical Officer, Dr. Steve Miller, whose rise to prominence as an articulate critic of drug industry prices symbolizes the growing clout of America's largest pharmacy benefit manager.

US researchers and regulators continue to support the use of randomized clinical trials to test potential treatments and vaccines to combat the Ebola virus, despite objections that this approach is unethical and unfair to vulnerable populations

The Food and Drug Administration is moving fast to implement the drug compounding provisions of new Drug Quality and Security Act (DQSA), issuing new guidance to spur registration by outsourcing facilities just days after President Obama signed the new bill into law.

For Moe Alsumidaie, the most concrete definition for patient centricity is “a dynamic process through which the patient regulates the flow of information to and from him/her via multiple pathways to exercise choice that is consistent with his/her preferences, values and beliefs.